MASI Stock Recent News

As of Oct. 10, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

MASI's R&D activities raise optimism about the stock.

AU, MASI, and SKM made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 1, 2024.

The medical technology specialist, known for its monitoring devices, named an interim CEO. This followed the resignation of its existing chief.

Masimo said on Wednesday that Joe Kiani has decided to resign as CEO, days after shareholders voted to remove him from the company's board.

Masimo (MASI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Shares of Masimo have risen since the news of a court ruling against Politan. The ruling is likely to favor MASI's founder in the upcoming vote for new board members on Sept.

NEW YORK--(BUSINESS WIRE)--Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today issued an open letter to shareholders in advance of the Company's 2024 Annual Meeting of Stockholders (the “Annual Meeting”), set for September 19. The full text of the letter is below: Dear Fellow Masimo Shareholders, Over the past several months, Politan and our independent director nominees have been fortu.

MASI Collaborates with Qualcomm to develop a reference platform for Wear OS smartwatches, combining biosensing tech and Snapdragon chips to enhance performance and connectivity.

After tangling in court with Apple over smartwatch features, medical technology company Masimo is teaming with Google. The company announced in a news release Saturday (Sept.